Evidence map›Paper›PMID 30221042›Full record

ArticleOncoimmunology

Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment.

Fréderic Franconieri, Samuel Deshayes, Hubert de Boysson, Salim Trad, Nicolas Martin Silva, Benjamin Terrier, Boris Bienvenu, Françoise Galateau-Sallé, Jean-François Emile, Alison C Johnson and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Fréderic FranconieriCHU de Caen, Department of Internal Medicine and Clinical Immunology, Caen, F-14000, France.
Samuel DeshayesCHU de Caen, Department of Internal Medicine and Clinical Immunology, Caen, F-14000, France.ORCID 0000-0001-8887-3233
Hubert de BoyssonCHU de Caen, Department of Internal Medicine and Clinical Immunology, Caen, F-14000, France.
Salim TradCHU Ambroise Paré - Université Paris Ouest, Department of Internal Medicine, Boulogne-Billancourt, France.ORCID 0000-0001-8927-9180
Nicolas Martin SilvaCHU de Caen, Department of Internal Medicine and Clinical Immunology, Caen, F-14000, France.
Benjamin TerrierHôpital Cochin, Department of Internal Medicine, Paris, France.
Boris BienvenuCHU de Caen, Department of Internal Medicine and Clinical Immunology, Caen, F-14000, France.
Françoise Galateau-SalléNational referent center MESOPATH-Base National Clinicobiologic Databasis MESOBANK Register multicenter MESONAT-Sante public cancer center of Léon Bérard, Department of Biopathology, Lyon, France.
Jean-François EmileDepartment of Pathology, Ambroise Paré Hospital & EA4340, Versailles, Boulogne, France.
Alison C JohnsonFrançois Baclesse Cancer Center, Department of Oncology, Caen, France.ORCID 0000-0002-4886-9544
Achille AoubaCHU de Caen, Department of Internal Medicine and Clinical Immunology, Caen, F-14000, France.
Centre Hospitalier Universitaire de Caen Normandie · FRHôpital Ambroise-Paré · FRCentre François Baclesse · FRHôpital Cochin · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

anakinraBRAF mutationErdheim-Chester diseaseNRAS mutationvemurafenib

Identifiers

PMID30221042
PMCPMC6136854
OpenAlexW2790276222

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.